Solaris Resources Inc. (CVE:SLS – Free Report) – Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Solaris Resources in a note issued to investors on Monday, November 18th. HC Wainwright analyst H. Ihle now forecasts that the company will earn ($0.56) per share for the year, down from their previous forecast of ($0.45). HC Wainwright currently has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Solaris Resources’ FY2025 earnings at ($0.44) EPS.
Solaris Resources Trading Down 2.7 %
Shares of CVE:SLS opened at C$6.15 on Wednesday. The firm has a 50 day moving average price of C$6.15. Solaris Resources has a 52 week low of C$1.38 and a 52 week high of C$7.09.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Stories
- Five stocks we like better than Solaris Resources
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- How to Most Effectively Use the MarketBeat Earnings Screener
- Williams-Sonoma Stock: Buy It and Never Let It Go
- How Can Investors Benefit From After-Hours Trading
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
